Print Page | Close Window

Ebola drugs show ‘90% survival rate’

Printed From: Avian Flu Talk
Category: Main Forums
Forum Name: Latest News
Forum Description: (Latest Breaking News)
URL: http://www.avianflutalk.com/forum_posts.asp?TID=39012
Printed Date: April 19 2024 at 5:02pm


Topic: Ebola drugs show ‘90% survival rate’
Posted By: EdwinSm,
Subject: Ebola drugs show ‘90% survival rate’
Date Posted: August 12 2019 at 9:38pm
The headline is modified by the fact that to get a 90% survival rate the drugs have to be given at an early stage.

Originally posted by BBC BBC wrote:

Four drugs were trialled on patients in the Democratic Republic of Congo, where there is a major outbreak of the virus.

Two of those were considerably more effective in treating the disease, the study found.

The drugs will now be used to treat all Ebola patients in DR Congo, according to health officials.
....
The drugs, named REGN-EB3 and mAb114, work by attacking the Ebola virus with antibodies, neutralising its impact on human cells.

They are the "first drugs that, in a scientifically sound study, have clearly shown a significant diminution in mortality" for Ebola patients, said Dr Anthony Fauci, director of NIAID.

REGN-EB3 and mAb114 were developed using antibodies harvested from survivors of Ebola, which has killed more than 1,800 people in DR Congo in the past year.

Two other treatments, called ZMapp and Remdesivir, have been dropped from trials as they were found to be less effective.
....
Of the patients given the two more effective drugs, 29% on REGN-EB3 and 34% on mAb114 died, NIAID said.

In contrast, 49% on ZMapp and 53% on Remdesivir died in the study, the agency said.

The survival rate among patients with low levels of the virus in their blood was as high as 94% when they were given REGN-EB3, and 89% when on mAb114, the agency said.

https://www.bbc.com/news/world-africa-49326505" rel="nofollow - Link to BBC



Replies:
Posted By: EdwinSm,
Date Posted: November 11 2021 at 3:24am

A new Ebola vaccine has entered the trial stage.   I am glad that SARS-CoV2 has not stopped work on other health conditions.


Originally posted by "BBC" "BBC" wrote:

Clinical trials have begun for a new Ebola vaccine developed by the University of Oxford. 

The jab has been designed to tackle the Zaire and Sudan types of Ebola, which together have caused nearly all Ebola outbreaks and deaths worldwide.

The University of Oxford has launched phase one of its trials, testing the vaccine in human volunteers.

<.....>

Phase one of the trials will see 26 people aged 18 to 55 receive one dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will then be monitored over a six-month period, with results expected in the second quarter of 2022.

https://www.bbc.com/news/uk-england-oxfordshire-59245679 - https://www.bbc.com/news/uk-england-oxfordshire-59245679




Print Page | Close Window